期刊
AMERICAN JOURNAL OF KIDNEY DISEASES
卷 61, 期 6, 页码 899-909出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.ajkd.2013.01.024
关键词
alpha-Klotho; fibroblast growth factor 23 (FGF-23); chronic kidney disease; kidney disease outcome
资金
- National Research Foundation of Korea
- Korea government [2012R1A1A1002575]
- Brain Korea 21 Project for Medical Science, Yonsei University
- Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea [A102065]
- National Research Foundation of Korea [2012R1A1A1002575] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Background: alpha-Klotho is reported to have protective effects against kidney injury, and its renal expression is decreased in many experimental models of kidney disease. However, circulating alpha-klotho levels in human chronic kidney disease (CKD) and the relationship to progression are unknown. Study Design: Post hoc analysis of a prospective cohort study. Setting & Participants: 243 of 301 participants from a CKD cohort at our institution between January 2006 and December 2011 were eligible for the study. Predictor: Baseline alpha-klotho levels. Outcomes: Primary outcome was the composite of doubling of baseline serum creatinine concentration, end-stage renal disease, or death. End-stage renal disease was defined as onset of treatment by renal replacement therapy. Measurements: Serum alpha-klotho and fibroblast growth factor 23 (FGF-23) were measured using enzyme-linked immunosorbent assay. Results: Lower serum alpha-klotho levels were associated with more severe CKD stage in the cross-sectional analysis of the baseline data (P for trend < 0.001). In the adjusted multivariable linear regression model, log(alpha-klotho) was associated independently with estimated glomerular filtration rate (beta = 0.154; P = 0.001). Cox regression analysis showed that baseline alpha-klotho level independently predicted the composite outcome after adjustment for age, diabetes, blood pressure, estimated glomerular filtration rate, proteinuria, parathyroid hormone level, and FGF-23 level (HR per 10-pg/mL increase, 0.96; 95% CI, 0.94-0.98; P < 0.001). When patients were categorized into 2 groups according to baseline median alpha-klotho value, 43 (35.2%) patients with alpha-klotho levels <= 396.3 pg/mL reached the primary composite outcome compared with 19 (15.7%) with alpha-klotho levels <396.3 pg/mL (HR, 2.03; 95% CI, 1.07-3.85; P = 0.03). Limitations: Uncontrolled dietary phosphorus intake and use of frozen samples. Conclusions: This observational study showed that low circulating alpha-klotho levels were associated with adverse kidney disease outcome, suggesting that alpha-klotho is a novel biomarker for CKD progression. More data from larger prospective longitudinal studies are required to validate our findings. (c) 2013 by the National Kidney Foundation, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据